Psychedelics Archives - Page 59 of 68

3 minute read

Psyched: Magic Mushrooms Vs. Psychotherapy, Psilocybin For Frontline Health Workers & Protecting Peyote

September 26, 1:39 PM

As news about psychedelics research and successful applications sweeps across the country and abroad, Psyched is back to wrap up the exciting movement of this rapidly evolving sector.

PSYGF

1 minute read

Magic Mushrooms For Anorexia? Clinical Study Receives FDA Approval For Phase 2 Trial

By Lara Goldstein

September 25, 12:16 PM

Origin Therapeutics Holdings Inc. (CSE: ORIG), a psychedelics industry-focused investment issuer, announced that one of its portfolio companies, Xpira Pharmaceuticals, has obtained approval from the FDA for its first Investigational New Drug (IND) application for a Phase 2a psilocybin therapy clinical study for anorexia nervosa.

CSE:ORIG

1 minute read

Clinical Study On DMT Inhaled Product For Treatment-Resistant Depression Completes Dosing Stage

By Lara Goldstein

September 23, 4:30 PM

Biomind Labs Inc. (OTC: BMNDF), a life sciences company developing medicinal next-generation psychedelics, completed the dose administration of 30 healthy subjects within its Phase 2 clinical trial of DMT-based proprietary drug BMND01 for the Treatment-Resistant Depression (TDR) disorder.

BMNDF

2 minute read

Ketamine Therapy Growing In US And Canada With This Novel Montreal Clinic

By Lara Goldstein

September 22, 3:52 PM

Legal ketamine-assisted therapy for people with diagnosed mental health conditions continues to expand throughout the U.S. and Canada.

DELCF

2 minute read

Two Psychedelics Companies Will Study Effects Of Natural Psilocybin And MDMA In Healthy Volunteers

By Lara Goldstein

September 22, 1:45 PM

Health Canada receives applications concerning clinical trials on a regular basis. This time, the licensed producer of natural EU-GMP psilocybin and MDMA Optimi Health Corp.

OPTHF

3 minute read

Why Magic Mushrooms Are Emerging As Major Part Of Public Discourse: What Science Is Saying

By Lara Goldstein

September 22, 10:28 AM

(Part three of a four-part series) Despite ongoing legal setbacks, psychedelics research has reemerged and it is proving that psilocybin reduces brain connections within the usual networks while amplifying links between less connected areas.

CMPS

3 minute read

This Ecotourism Resort In Jamaica Now Offers Psilocybin Microdosing Retreats And Experiences

By Javier Hasse

September 21, 1:29 PM

Jamaica is getting its own ecotourism and psilocybin microdosing resort and retreat center.

SILFF

2 minute read

Clinical Research Comparing Effects Of Novel MDMA Matches In Healthy Patients Begins In Switzerland

By Lara Goldstein

September 20, 2:28 PM

The clinical trial investigating the effects of MDMA analogs in healthy volunteers led by PI Prof. Dr. Matthias Liechti and supported by psychedelics biotech company Mind Medicine Inc. (NASDAQ: MNMD) has begun patient dosing.

MNMD

2 minute read

Toronto Residents Get New Ketamine-Assisted Therapy Option Close To Home

By Lara Goldstein

September 19, 1:20 PM

The Neurology Centre of Toronto (NCT), located in a midtown neighborhood and owned by Numinus Wellness Inc. (OTCQX: NUMIF), is offering ketamine-assisted therapy for patients with neurologic conditions diagnoses.

NUMIF